Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ CDK Inhibitor May Benefit From Swing Back To Single-Arm Trials

Executive Summary

As FDA looks toward more flexible cancer drug development standards, advisory panel indicates Novartis’ proposed pediatric indications for CDK inhibitor could be candidate for single-arm studies.

You may also be interested in...



Novartis Puts Combination, Cellular Therapies In Spotlight As It Revamps R&D Portfolio

Novartis says it has entered a transformational period of growth as its oncologic products continue to advance and its focus expands to include dedicated R&D units for dermatology, heart failure, respiratory and cell therapy.

Novartis Puts Combination, Cellular Therapies In Spotlight As It Revamps R&D Portfolio

Novartis says it has entered a transformational period of growth as its oncologic products continue to advance and its focus expands to include dedicated R&D units for dermatology, heart failure, respiratory and cell therapy.

The Next Phase In Oncology: FDA’s Pazdur Has New Vision For Drug Development

FDA’s top cancer drug reviewer has taken to the podium to paint a picture of the next phase in cancer drug development, which includes new business models, a return to single-arm trials and a new emphasis on safety.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel